Search results
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
Zacks· 2 days agoThe RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the CDC's recommendation, it will be launched in the 2024-2025 respiratory virus season.
Everything Congress SHOULD HAVE Asked Fauci About COVID-19 | News Talk 99.5 WRNO | The Glenn Beck...
iHeartRadio· 2 days agoWith Dr. Fauci testifying before a House subcommittee on the origins of COVID-19, many thought he...
US FDA approves Moderna’s RSV vaccine, its second marketed product
WHTC 1450 Holland· 4 days agoBy Patrick Wingrove (Reuters) - The U.S. Food and Drug Administration has approved Moderna's...
Moderna’s stock climbs on report that bird-flu vaccine funding is near
Market Watch· 5 days agoModerna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a...
Moderna just got FDA approval for its RSV vaccine — only its second product on the market
Quartz· 4 days agoThe Food and Drug Administration on Friday approved Moderna’s mRNA-based respiratory syncytial virus...
Moderna's RSV vaccine for older adults approved
Axios· 4 days agoModerna's RSV shot for adults 60 and older was approved by the Food and Drug Administration on Friday, joining a growing group of vaccines protecting...
Moderna Looks for Boost From Newly Approved RSV Shot
The Wall Street Journal· 4 days agoModerna, the biotech that rose to fame for making one of the world’s first Covid-19 vaccines, has hit a new milestone: its first non-Covid product, which...
US approves Moderna's RSV vaccine for older adults
AFP via Yahoo News· 4 days agoThe US Food and Drug Administration on Friday approved Moderna's respiratory syncytial virus (RSV) vaccine for older adults -- marking the first time any...
Moderna’s vaccine for RSV gets FDA approval for people 60 and older - The Boston Globe
The Boston Globe· 4 days agoModerna said Friday that US drug regulators have approved its second product, a vaccine for...
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma...
Benzinga· 1 day agoMonday, Moderna Inc MRNA and Merck & Co Inc MRK announced the first presentation of results from a planned analysis from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study. The ...